Printable Schedule-at-a-Glance (Updated: 03/03/2016)
Registration and Continental Breakfast
Welcome and Opening Remarks
An Overview of the Blood/Marrow Transplant (BMT) Process, Robert H. Collins, Jr., MD, University of Texas Southwestern Medical Center
With recent developments in techniques, indications, and supportive therapy, BMT continues to be an advancing field in the treatment of disease, with increased frequency in its use for treating numerous malignant and nonmalignant diseases.
This session will describe the different types of BMTs and the sources of stem cells, as well as explain the pretransplant evaluation process, engraftment, and posttransplant complications. It will also provide an understanding of remission and chemo-sensitive disease; the significance of clinical trials; and the importance of a multidisciplinary team approach to achieve optimal outcomes in patients undergoing BMT.
Break — Exhibits Open
The Management of Infections in BMT Recipients, Sanjeet S. Dadwal, MD, FACP, City of Hope National Medical Center
Certain factors place patients undergoing BMT at increased risk for infections. Despite recent advances in supportive care, growth factors, more-potent antimicrobials, prophylaxis strategies, and new diagnostic techniques, infection and graft-vs-host disease (GVHD) remain the major causes of mortality in patients who undergo BMT.
This session will discuss the management of opportunistic infections and GVHD among BMT recipients.
Pharmaceuticals in BMT, Jill K. Leslie, PharmD, BCPS, BCOP, Indiana Blood and Marrow Transplant
Patients undergoing BMT require a number of prescription medications pre- and posttransplant, including immunosuppressants to control GVHD; immune system “boosters” for red and white blood cells and platelets; and medication to prevent infections. This session will discuss medications used during BMT, as well as immunosuppression therapy and its role in BMT pre- and posttransplant.
Luncheon Presentation — An Overview of Optum™ (nonaccredited/optional; lunch provided)
Dessert Break — Exhibits Open
National Marrow Donor Program (NMDP): A Resource for Unrelated Donors, Jeffrey W. Chell, MD, National Marrow Donor Program
Thousands of patients diagnosed with blood cancers and other life-threatening diseases depend on BMTs to save their lives. And there are millions of people on the Be the Match Registry® (operated by the NMDP) and other registries throughout the world, who stand ready to donate the cells needed for transplants for patients in need.
This session will provide a global overview of the role of the NMDP as it relates to allogeneic transplantation and the use of unrelated BMT donors.
Cancer Immunotherapy: Basic Principles, Mechanisms and Applications, Michael R. Bishop, MD, University of Chicago Medicine
Cancer immunotherapy — treatments that harness and enhance the innate powers of the immune system to fight cancer — has become critically important over the last few decades in bringing new and potentially lifesaving treatments to patients with certain types of cancers, and it will continue to impact how cancer is treated in the future. These treatments have the potential to achieve complete, long-lasting remissions and cancer cures, with few or no side effects. This session will review basic principles of immunology and the characteristics of an immune response, along with the treatment considerations of cancer immunotherapy.
Break — Exhibits Open
BMT: Trends in Patients Aged 65 and Older with Cancer, Vivek Roy, MD, Mayo Clinic, Jacksonville
Blood cancers, including leukemia, lymphoma, and multiple myeloma, are most common in people age 65 and older. The percentage of older BMT recipients is significantly greater than a decade ago, when patients over the age of 55 were excluded from BMT treatment due to concerns for chemotherapy toxicity. However, reduced-intensity chemotherapy, improved supportive care, and Medicare changes have made it possible for patients age 65 and older to obtain potentially lifesaving BMT therapy. This session will review common diagnoses treated by BMT in the older adult and the role of reduced-intensity donor stem cell transplantation, as well as Medicare coverage for these treatments.
Challenges in the Care of Children and Adolescent Young Adults (AYA) Undergoing Transplantation, Kenneth R. Cooke, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Life-threatening diseases, such as cancer, in the pediatric and AYA populations cross many diagnoses and continue to grow in frequency of their occurrence. Treatment options may include blood/marrow and organ transplantation, which can cause multiple psychosocial issues and require a unique management approach. This session will discuss the variables and complexities that can influence the level of psychosocial functioning in children and AYA who have cancer or have had a transplant, as well as the barriers and concerns health care professionals face in managing these patients.
Complimentary Get-Acquainted Reception — Exhibits Open
Registration and Continental Breakfast — Exhibits Open
Thoracic Transplantation 101: Evaluation, Hospitalization, Posttransplant Care and Complications, Michael Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Health
Heart and lung transplantation have revolutionized therapy for end-stage thoracic disease in the last decade. There are important factors that need to be taken into consideration to optimize outcomes for this patient population. The appropriate timing for referral to a transplant program is based on the patient’s functional status and life expectancy. With thoracic transplantation, there is a significant risk of perioperative morbidity and mortality; therefore, each patient needs to be evaluated individually, with consideration for absolute and relative contraindications. This session will discuss the advantages of a comprehensive multidisciplinary approach to managing thoracic transplant recipients. An overview of the criteria and evaluation process for thoracic transplantation, hospital course, and pre- and posttransplant management strategies will be presented along with how a team can work together to achieve optimal patient outcomes.
Left Ventricular Assist Devices (LVADs): Optimal Management to Reduce Morbidity and Mortality in Heart Failure Patients, Michael Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Health
An LVAD is a mechanical pump that is used to support heart function and blood flow in people who have weakened hearts. This treatment option is for certain patients with end-stage heart failure and can be used either as a bridge to transplant until a donor heart becomes available for transplant or as destination therapy as an alternative to heart transplant. This session will review (1) candidate selection; (2) management strategies to reduce morbidity and mortality in heart failure patients supported with LVADs; (3) outpatient strategies to optimize device performance and heart failure management; and (4) important device complications that warrant close outpatient monitoring.
Break — Exhibits Open
Abdominal Transplantation 101: Treatable Diseases, Evaluation, Hospitalization and Posttransplant Care, George E. Loss, Jr., MD, PhD, FACS, Ochsner Medical Center
Organ transplantation has overcome major technical limitations to become the success it is today. The breakthroughs include developing techniques for vascular anastomoses and managing the immune response.The outcomes of organ transplantation continue to improve with advancements in the evaluation and selection process, as well as the peri- and postoperative management of these patients. This session will include an overview of abdominal organ transplantation, organ-specific outcomes, the use of deceased versus living donors, the role of immunosuppression therapy, and short- and long-term complications associated with these surgeries — such as infection, disease recurrence, and acute and chronic rejection.
An Overview of Pharmaceuticals Utilized in Organ Transplantation, Andrew Freeman, PharmD, BCPS, Ochsner Medical Center
The success of solid organ transplantation rests heavily on the major advances in immunosuppressive therapy. With the introduction of improved immunosuppressive agents to prevent graft rejection, as well as antimicrobials and antifungal agents to decrease the risk of opportunistic infection, successful organ transplantation has become the standard. The use of risk education and management strategies (REMS) are becoming increasingly common in organ transplantation, and studies suggest that health care providers must be aware of these strategies to improve patient education and reduce pharmaceutical risk. This session will discuss immunosuppressive agents used in organ transplantation and the major adverse effects for each agent.
Luncheon Presentation — Organ Procurement: Strategies to Close the Gap Between the Supply and Demand for Organs, Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital
Organ transplantation has been limited by the shortage of donor organs, resulting in a significant imbalance between organ availability and the need for organ transplantation services. Despite advances in medicine and technology, as well as increased awareness of organ donation and transplantation, the gap between supply and demand continues to widen. The U.S. Organ Procurement and Transplantation Network (OPTN) helps ensure the success and efficiency of the U.S. organ transplantation system. This session will review the goals of the OPTN and discuss strategies to increase organ donation that will close the gap between suppy and demand.
Dessert Break — Exhibits Open
Immune Tolerance in Kidney and Liver Transplantation: What’s New? R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed), Methodist J.C. Walter Jr. Transplant Center
One of the biggest battles associated with organ transplantation is the management of side effects resulting from lifelong use of immunosuppression. The toxicity of chronic immunosuppressive agents has prompted investigators to pursue approaches to induce immune tolerance. The goal is to wean transplant recipients off immunosuppressive agents while keeping graft function stable, in the hope of making it possible for patients to live without the need for immunosuppressive drugs. This session will offer information about novel agents that produce immune tolerance, including chimerism and donor-specific tolerance in kidney and liver transplant recipients.
Congenital Heart Disease (CHD): Incidence, Diagnosis, Complications and Management, Wayne J. Franklin, MD, FACC, Texas Children's Hospital, Baylor St. Luke's Medical Center
According to the Centers for Disease Control (CDC), 1 percent of babies born in the United States have congenital heart defects. They range from simple defects with no symptoms to complex defects with severe, life-threatening symptoms. The diagnosis and treatment of CHD has greatly improved over the past few decades and, as a result, almost all children who have complex heart defects survive to adulthood and can live active, productive lives. With this increased longevity, children with CHD grow out of needing pediatric care, and health care providers who take care of adults are now managing this patient population. Studies suggest that this transition may be challenging, and health care providers do not always know the best way to smoothly transition care for these patients This session will review the types, signs and symptoms, diagnoses, and treatments for complex CHD. It will also review the impact congenital heart defects have on quality of life and self-efficacy in children and adults with this disease and the challenges that children face as they transition from pediatric to adult care.
Chronic Kidney Disease (CKD): Overcoming Barriers to Patient Care and to Successful Implementation of Clinical Guidelines, Cybele Ghossein, MD, Northwestern Medicine
The CDC reports that over 20 million adults in the United States suffer from CKD. Despite the presence of clinical guidelines, including those created by the National Kidney Foundation, studies suggest that there are numerous barriers to implementation, such as patient-, provider- and system-associated barriers. This session will review the latest treatment guidelines for CKD, outline a model to identify at-risk patients and discuss how to effectively overcome barriers to care. It will also review the importance of optimal timing for referral of CKD patients to a nephrologist.
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last updated: 03/03/16